MicroRNA-183 is involved in cell proliferation, survival and poor prognosis in pancreatic ductal adenocarcinoma by regulating Bmi-1

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1734-1740

  Zhou, Liang ^a   Zhang, Wei Guo ^a   Wang, De Sheng ^b   Tao, Kai Shan ^b   Song, Wen Jie ^b   Dou, Ke Feng ^b  

^a The 155 Central Hospital of PLA   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Bmi 1; MicroRNA 183; Overall survival; Pancreatic ductal adenocarcinoma; Proliferation

Indexed keywords

BMI1 PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; MICRORNA; MICRORNA 183; UNCLASSIFIED DRUG; BMI1 PROTEIN, HUMAN; MIRN183 MICRORNA, HUMAN;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 1; PROGNOSIS; TUMOR STEM CELL ASSAY;

EID: 84923068444     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3374     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008. (Pubitemid 351521864)
2. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
3. Pillai RS, Bhattacharyya SN, Artus CG, et al: Inhibition of translational initiation by Let-7 microRNA in human cells. Science 309: 1573-1576, 2005. (Pubitemid 41266485)
4. Zamore PD and Haley B: Ribo-gnome: the big world of small RNAs. Science 309: 1519-1524, 2005. (Pubitemid 41266468)
5. Bastian BC, LeBoit Pe, Hamm H, Bröcker eB and Pinkel D: Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58: 2170-2175, 1998. (Pubitemid 28232904)
6. Motoyama K, inoue H, Takatsuno Y, et al: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol 34: 1069-1075, 2009.
7. Lin WM, Baker AC, Beroukhim R, et al: Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 68: 664-673, 2008. (Pubitemid 351206741)
8. Wang G, Mao W and Zheng S: MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 582: 3663-3668, 2008.
9. Ambros V and Lee RC: identification of microRNAs and other tiny noncoding RNAs by cDNA cloning. Methods Mol Biol 265: 131-158, 2004.
10. Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118-126, 2007. (Pubitemid 46357525)
11. Caldas C and Brenton JD: Sizing up miRNAs as cancer genes. Nat Med 11: 712-714, 2005. (Pubitemid 41021196)
12. Kefas B, godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572, 2008.
13. Ladeiro Y, Couchy G, Balabaud C, et al: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology 47: 1955-1963, 2008. (Pubitemid 351952843)
14. + cells increases USF2-mediated cell growth. Mol Cancer Res 6: 1830-1840, 2008.
15. Mattie MD, Benz CC, Bowers J, et al: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 5: 24, 2006.
16. Lowery AJ, Miller N, Dwyer RM and Kerin MJ: Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer 10: 502, 2010.
17. Wellner U, Schubert J, Burk UC, et al: The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11: 1487-1495, 2009.
18. Jacobs JJ and van Lohuizen M: Polycomb repression: from cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 1602: 151-161, 2002. (Pubitemid 34521793)
19. Kondo Y, Shen L, Cheng AS, et al: Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 40: 741-750, 2008. (Pubitemid 351748874)
20. Raaphorst FM: Deregulated expression of Polycomb-group oncogenes in human malignant lymphomas and epithelial tumors. Hum Mol Genet 14 (Spec No 1): R93-R100, 2005.
21. van Lohuizen M, Verbeek S, Scheijen B, Wientjens e, van der gulden H and Berns A: identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging. Cell 65: 737-752, 1991. (Pubitemid 121001306)
22. Liu S, Dontu G, Mantle ID, et al: Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 66: 6063-6071, 2006.
23. Jacobs JJ, Kieboom K, Marino S, DePinho RA and van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164-168, 1999. (Pubitemid 29050921)
24. Dimri GP, Martinez JL, Jacobs JJ, et al: The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62: 4736-4745, 2002.
25. Mihic-Probst D, Kuster A, Kilgus S, et al: Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer 121: 1764-1770, 2007. (Pubitemid 47417295)
26. effendi K, Mori T, Komuta M, Masugi Y, Du W and Sakamoto M: Bmi-1 gene is upregulated in early-stage hepatocellular carcinoma and correlates with ATP-binding cassette transporter B1 expression. Cancer Sci 101: 666-672, 2010.
27. Sasaki M, ikeda H, itatsu K, et al: The overexpression of polycomb group proteins Bmi-1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 88: 873-882, 2008.
28. Wang H, Pan K, Zhang HK, et al: Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol 134: 535-541, 2008. (Pubitemid 351422607)
29. Song W, Tao K, Li H, et al: Bmi-1 is related to proliferation, survival and poor prognosis in pancreatic cancer. Cancer Sci 101:1754-1760, 2010.
30. Sparmann A and van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856, 2006. (Pubitemid 44629896)
31. Li DW, Tang HM, Fan JW, et al: Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol 136: 997-1006, 2010.
32. Liu JH, Song LB, Zhang X, et al: Bmi-1 expression predicts prognosis for patients with gastric carcinoma. J Surg Oncol 97: 267-272, 2008. (Pubitemid 351312168)
33. Song LB, Zeng MS, Liao WT, et al: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 66: 6225-6232, 2006.
34. Jiang Y, Su B, Meng X, et al: Effect of siRNA-mediated silencing of Bmi-1 gene expression on HeLa cells. Cancer Sci 101: 379-386, 2010.